Use of pharmacogenetics to optimize immunosuppressive therapy

Therapeutic Drug Monitoring

Volumn 32, Issue 3, 2010, Pages 261-264

  MacPhee, Iain A M ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Immunosuppression; Pharmacogenetics; Tacrolimus; Therapeutic drug monitoring; Transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYTOCHROME P450 3A5; GLUCURONOSYLTRANSFERASE 1A9; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; AUTOIMMUNE DISEASE; BLOOD TOXICITY; CELL LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG TRANSPORT; FIRST PASS EFFECT; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HISTOCOMPATIBILITY; HUMAN; IMMUNOGENETICS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; LIVER GRAFT REJECTION; LOADING DRUG DOSE; PHARMACOGENETICS; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM;

CYCLOSPORINE; CYTOCHROME P-450 CYP3A; GENOTYPE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY TRANSPLANTATION; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SIROLIMUS; TACROLIMUS;

EID: 77952954641     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181dca995     Document Type: Conference Paper

References (24)

1. Undre NA, van Hoof J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc. 1999;31:296-298.
2. Clase CM, Mahalati K, Kiberd BA, et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant. 2002;2:789-795.
3. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008;86:1043-1051.
4. Le Meur Y, Djebli N, Szelag JC, et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther. 2006;80:51-60.
5. Hesselink DA, Ngyuen H, Wabbijn M, et al. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br J Clin Pharmacol. 2003;56:327-330.
6. Kirwan CJ, Lee T, Holt DW, et al. Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients. Intensive Care Med. 2009;35:1271-1275.
7. Michaud J, Dube P, Naud J, et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol. 2005;144:1067-1077.
8. Kuypers DR, Vanrenterghem Y, Squifflet JP, et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit. 2003;25:609-622.
9. Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit. 2004;26:186-191.
10. Levy G, Thervet E, Lake J, et al. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation. 2002; 73:S12-S18.
11. Andrews PA, Sen M, Chang RWS. Racial variation in dosage requirements of tacrolimus. Lancet. 1996;348:1446.
12. Vadivel N, Garg A, Holt DW, et al. Tacrolimus dose in black renal transplant recipients. Transplantation. 2007;83:997-999.
13. Ekbal NJ, Holt DW, Macphee IA. Pharmacogenetics of immunosuppres-sive drugs: prospect of individual therapy for transplant patients. Pharmacogenomics. 2008;9:585-596.
14. Macphee IA, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant. 2004;4:914-919.
15. Thervet E, Loriot MA, Barboni F, et al. Final results of pretransplant pharmacogenetic adaptation of tacrolimus treatment after renal transplantation. Transpl Int. 2009;22(Suppl 2):67.
16. Uesugi M, Masuda S, Katsura T, et al. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics. 2006;16:119-127.
17. Anglicheau D, Le Corre D, Lechaton S, et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant. 2005;5:595-603.
18. Macphee I, Moreton M, Holt DW. The influence of CYP3A5 genotype on blood sirolimus concentrations following switch from a calcineurin inhibitor. Transplantation. 2008:86(Suppl):332.
19. van Schaik RH, van Agteren M, de Fijter JW, et al. UGT1A9-275T. A/-2152C.T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther. 2009;86:319-327.
20. Wang J, Yang JW, Zeevi A, et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther. 2008;83:711-717.
21. Shaw LM, Pawinski T, Korecka M, et al. Monitoring of mycophenolic acid in clinical transplantation. Ther Drug Monit. 2002;24: 68-73.
22. Crettol S, Venetz JP, Fontana M, et al. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics. 2008;18:307-315.
23. Capron A, Musuamba F, Latinne D, et al. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in peripheral blood mononuclear cells. Ther Drug Monit. 2009;31:178-186.
24. Brunet M, Cattaneo D, Haufroid V, et al. Clinical Implementation for Pharmacogenetics of Immunosuppressive Drugs: European Multicentric Report. Barcelona; 2009. Available at: http://www.iatdmct.org/. Accessed November 27, 2009.